{"id":"alprazolam","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Impaired coordination","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypotension","drugRate":"","severity":"common","organSystem":""},{"effect":"Dysarthria","drugRate":"","severity":"common","organSystem":""},{"effect":"Increased libido","drugRate":"","severity":"common","organSystem":""},{"effect":"Sedation","drugRate":"","severity":"common","organSystem":""},{"effect":"Slurred speech","drugRate":"","severity":"common","organSystem":""},{"effect":"Loss of coordination","drugRate":"","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"","severity":"common","organSystem":""},{"effect":"Concentration difficulties","drugRate":"","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"","severity":"common","organSystem":""},{"effect":"Dystonia","drugRate":"","severity":"common","organSystem":""},{"effect":"Transient amnesia or memory impairment","drugRate":"","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"","severity":"common","organSystem":""},{"effect":"Musculoskeletal weakness","drugRate":"","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Diplopia","drugRate":"","severity":"common","organSystem":""},{"effect":"Menstrual irregularities","drugRate":"","severity":"common","organSystem":""},{"effect":"Incontinence","drugRate":"","severity":"common","organSystem":""},{"effect":"Urinary retention","drugRate":"","severity":"common","organSystem":""},{"effect":"Changes in libido","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Alcohol intoxication","Angle-closure glaucoma","Asthenia","Breastfeeding (mother)","Central nervous system depression","Chronic lung disease","Depressive disorder","Disease of liver","Kidney disease","Obesity","Open-angle glaucoma","Pregnancy, function","Sleep apnea","Smokes tobacco daily","Substance abuse","Suicidal thoughts","Syncope"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Withdrawal seizures","drugRate":"","severity":"serious"},{"effect":"Hallucinations","drugRate":"","severity":"serious"},{"effect":"Depersonalization","drugRate":"","severity":"serious"},{"effect":"Jaundice","drugRate":"","severity":"serious"},{"effect":"Hepatic failure","drugRate":"","severity":"serious"},{"effect":"Hepatitis","drugRate":"","severity":"serious"},{"effect":"Mania","drugRate":"","severity":"serious"},{"effect":"Hypomania","drugRate":"","severity":"serious"},{"effect":"Aggressive or hostile behavior","drugRate":"","severity":"serious"}]},"status":"approved","trials":["NCT00803400","NCT03220113","NCT06097676","NCT00975481","NCT01322867","NCT00860119","NCT01188031","NCT03948243","NCT01046162","NCT00647634","NCT06874452","NCT07020988","NCT02570581","NCT00647894","NCT03702803","NCT00004373","NCT02374567","NCT00865761","NCT00266409","NCT06757140","NCT00426608","NCT07154147","NCT00650299","NCT01577706","NCT03398083","NCT07275710","NCT02648776","NCT00555139","NCT06293638","NCT01161472","NCT01893632","NCT03327506","NCT05006079","NCT06826417","NCT00878514","NCT04970342","NCT03130842","NCT01546896","NCT04715269","NCT01549691","NCT04658732","NCT00635531","NCT05737511","NCT03297944","NCT05076617","NCT01949038","NCT02033707","NCT01486615","NCT03012334","NCT04857307"],"aliases":["Xanax","Xanax XR"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0245/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$9","description":"ALPRAZOLAM 0.25 MG TABLET","retrievedDate":"2026-04-07"}],"allNames":"xanax","offLabel":[],"timeline":[],"aiSummary":"Alprazolam (Xanax) is the most prescribed benzodiazepine, developed by Upjohn and approved in 1981. Effective for panic disorder but carries significant dependence and withdrawal risks. Schedule IV controlled substance. Available generically.","brandName":"Xanax","companyId":"unknown","ecosystem":[],"mechanism":{"target":"Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4","novelty":"","modality":"Small molecule","drugClass":"Benzodiazepine (triazolobenzodiazepine)","explanation":"Alprazolam is the most prescribed benzodiazepine and one of the most prescribed psychiatric medications overall. Its rapid onset provides fast anxiety relief but its short half-life (6-12 hours) and high potency create significant dependence potential. Discontinuation requires slow tapering to avoid seizures. Schedule IV controlled substance with high abuse potential.","oneSentence":"Short-acting, high-potency benzodiazepine that enhances GABA-A receptor activity, providing rapid anxiolytic relief.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Generic (originally Upjohn/Pfizer)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"alprazolam","indications":{"approved":[{"name":"Anxiety","diseaseId":"anxiety","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Generalized anxiety disorder","diseaseId":"generalized-anxiety-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mixed anxiety and depressive disorder","diseaseId":"mixed-anxiety-and-depressive-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Panic disorder","diseaseId":"panic-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00803400","phase":"Phase 4","title":"Efficacy of Aerobic Exercise Added to Alprazolam in Panic Disorder Treatment: a Clinical Randomized Trial","status":"COMPLETED","sponsor":"University of Buenos Aires","isPivotal":false,"enrollment":150,"indication":"Panic Disorder","completionDate":"2009-09-30"},{"nctId":"NCT03220113","phase":"Phase 1","title":"Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches.","status":"UNKNOWN","sponsor":"Corona Doctors Medical Clinics, Inc.","isPivotal":false,"enrollment":100,"indication":"Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura","completionDate":"2019-07-01"},{"nctId":"NCT06097676","phase":"Phase 4","title":"A Randomized, Double Blind, Active and Placebo Controlled, 5 Way Crossover Study to Determine the Abuse Potential of Orally Administered Gabapentin Enacarbil Immediate Release Capsules in Healthy, Non","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","isPivotal":false,"enrollment":86,"indication":"Abuse Potential","completionDate":"2022-06-30"},{"nctId":"NCT00975481","phase":"Phase 1","title":"A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":36,"indication":"Alzheimer's Disease, Huntington's Disease","completionDate":"2010-02"},{"nctId":"NCT01322867","phase":"Phase 4","title":"A Phase IV, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine Relative Bioavailability of Alprazolam 0,75mg/ml (laboratórios Pfizer Ltda) in the Oral Solution-drops Form, Versu","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":30,"indication":"Healthy","completionDate":"2011-09"},{"nctId":"NCT00860119","phase":"Phase 1","title":"Open-Label, Randomized, Single-Dose, 2-Way Crossover Pivotal Bioequivalence Study Comparing Alprazolam Immediate Release (IR) Tablets (Administered Orally) And Alprazolam Sublingual (SL) Tablets (Admi","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":23,"indication":"Healthy","completionDate":"2009-10"},{"nctId":"NCT01188031","phase":"Phase 1","title":"A Relative Bioavailability Study of 2 mg Alprazolam Oral Disintegrating Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":"2006-07"},{"nctId":"NCT03948243","phase":"Phase 1","title":"Licorice Botanical Dietary Supplements - Metabolism and Safety in Women","status":"COMPLETED","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":19,"indication":"Food-drug Interaction","completionDate":"2022-04-22"},{"nctId":"NCT01046162","phase":"Phase 1","title":"An Open Label,Crossover,Randomized Study Of Two Periods,Two Treatments,Two Sequences, And A Single Dose Of Two Oral Drug Products Of Alprazolam 2mg (Tafil (r), Product Of Pharmacia& Upjohn S.a De C.v ","status":"WITHDRAWN","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":0,"indication":"Healthy","completionDate":"2010-07-22"},{"nctId":"NCT00647634","phase":"Phase 1","title":"Single-Dose Fasting In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (3 mg; Mylan) to Xanax XR® Tablets (3 mg; Pharmacia & Upjohn) in Healthy Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":21,"indication":"Healthy","completionDate":"2004-08"},{"nctId":"NCT06874452","phase":"Phase 4","title":"Pain, Anxiety and Anesthetic Satisfaction for Patient With Different State Anxiety Underwent Cataract Surgery With Topical Anesthesia. An Extension Test of Whether to Use Oral Anti-anxiety Drugs (XANA","status":"RECRUITING","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":250,"indication":"Ophthalmology, Cataract Surgery Anesthesia","completionDate":"2027-12-31"},{"nctId":"NCT07020988","phase":"Phase 1","title":"An Open Label, Single Dose, Randomized, Active Comparator, Quantitative Electroencephalogram Crossover Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Intravenous Midazolam a","status":"COMPLETED","sponsor":"UCB Biopharma SRL","isPivotal":false,"enrollment":55,"indication":"Healthy Participants","completionDate":"2026-01-21"},{"nctId":"NCT02570581","phase":"Phase 1","title":"MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","isPivotal":false,"enrollment":16,"indication":"Healthy","completionDate":"2014-07"},{"nctId":"NCT00647894","phase":"Phase 1","title":"Single-Dose Fasting In Vivo Bioequivalence Study of Alprazolam Extended-Release Tablets (1 mg; Mylan) to Xanax XR Tablets (1 mg; Pharmacia & Upjohn) in Healthy Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":"2005-01"},{"nctId":"NCT03702803","phase":"Phase 2","title":"Efficacy and Safety Study of a IMSS Developed Phytopharmaceutical for the Treatment of Anxiety. Double Blind and Randomized Clinical Trial Controlled With Alprazolam","status":"UNKNOWN","sponsor":"Coordinación de Investigación en Salud, Mexico","isPivotal":false,"enrollment":122,"indication":"Generalized Anxiety Disorder","completionDate":"2020-10-19"},{"nctId":"NCT00004373","phase":"Phase 2","title":"","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","isPivotal":false,"enrollment":80,"indication":"Anxiety Disorder, Panic Disorder","completionDate":"2001-03"},{"nctId":"NCT02374567","phase":"Phase 3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","isPivotal":true,"enrollment":407,"indication":"Dementia, Depression","completionDate":"2017-06-28"},{"nctId":"NCT00865761","phase":"Phase 1","title":"A Relative Bioavailability Study of 3 mg Alprazolam Extended Release Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","isPivotal":false,"enrollment":40,"indication":"Healthy","completionDate":"2005-09"},{"nctId":"NCT00266409","phase":"Phase 4","title":"A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":418,"indication":"Generalized Anxiety Disorder, Panic Disorder","completionDate":"2006-06"},{"nctId":"NCT06757140","phase":"Phase 1","title":"Opioid Drug Interactions: Safety, Abuse Potential and Pharmacokinetic Effects","status":"RECRUITING","sponsor":"Shanna Babalonis, PhD","isPivotal":false,"enrollment":25,"indication":"Drug Interactions, Drug Kinetics","completionDate":"2029-06-01"},{"nctId":"NCT00426608","phase":"Phase 1","title":"Placebo-Controlled, Randomized, Blinded, Double-Dummy, Crossover Study to Investigate the Attenuation of ACTH Activation Induced by Metyrapone With a Single Dose of GSK561679 or Alprazolam in Healthy ","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":20,"indication":"Depressive Disorder and Anxiety Disorders","completionDate":"2007-01-08"},{"nctId":"NCT07154147","phase":"Phase 4","title":"Cataract Oral vs IV Sedation Pilot RCT: A Non-inferiority Assessment of Perioperative Safety and Cognitive Recovery in Older Adults","status":"RECRUITING","sponsor":"University of California, San Francisco","isPivotal":false,"enrollment":20,"indication":"Cataract Surgery, Sedation","completionDate":"2025-11"},{"nctId":"NCT00650299","phase":"Phase 1","title":"Single-Dose Food In Vivo Bioequivalence Study of Alprazolam Extended-release Tablets (3 mg; Mylan) to Xanax XR® Tablets (3 mg; Pharmacia & Upjohn) in Healthy Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":21,"indication":"Healthy","completionDate":"2004-08"},{"nctId":"NCT01577706","phase":"NA","title":"Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study","status":"TERMINATED","sponsor":"Mclean Hospital","isPivotal":false,"enrollment":7,"indication":"AOD Effects and Consequences","completionDate":"2013-12"},{"nctId":"NCT03398083","phase":"Phase 1","title":"A Human Abuse Potential Study to Evaluate the Subjective and Physiological Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam in an Inpatient Setting","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","isPivotal":false,"enrollment":42,"indication":"Cannabis Use Disorder","completionDate":"2018-05-30"},{"nctId":"NCT07275710","phase":"NA","title":"Role of Alprazolam in Management of Post Endodontic Pain After Single Visit Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi","isPivotal":false,"enrollment":110,"indication":"Pain","completionDate":"2027-02-01"},{"nctId":"NCT02648776","phase":"N/A","title":"Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly; A Prospective Cohort Study at a Taiwanese Academic Medical Center","status":"UNKNOWN","sponsor":"China Medical University Hospital","isPivotal":false,"enrollment":1400,"indication":"Sleep Disorders","completionDate":"2018-12"},{"nctId":"NCT00555139","phase":"Phase 1","title":"Double-blind, Randomized, Placebo and Alprazolam-controlled Three-period Crossover Incomplete Block Design Study to Compare Putative Anxiolytic-like fRMI Activity of GW876008 and GSK561679 After Singl","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":35,"indication":"Social Phobia","completionDate":"2008-01-10"},{"nctId":"NCT06293638","phase":"N/A","title":"Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor","status":"RECRUITING","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":55,"indication":"Essential Tremor","completionDate":"2026-12-31"},{"nctId":"NCT01161472","phase":"Phase 1","title":"A 4 Way Placebo And Active Controlled Study To Evaluate The Effects Of Fesoterodine On Cognitive Function In Healthy Elderly Subjects","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":20,"indication":"Healthy","completionDate":"2010-09"},{"nctId":"NCT01893632","phase":"Phase 2","title":"Gabapentin Treatment of Benzodiazepine Dependence","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","isPivotal":false,"enrollment":2,"indication":"Benzodiazepine Dependence","completionDate":"2016-04-01"},{"nctId":"NCT03327506","phase":"Phase 4","title":"Efficacity of Hypnosis Versus Premedication for the Management of Perioperative Anxiety in Gynecological Surgery","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","isPivotal":false,"enrollment":128,"indication":"Gynecologic Disease, Anxiety Disease","completionDate":"2021-12"},{"nctId":"NCT05006079","phase":"Phase 2","title":"Opioid/Benzodiazepine Polydrug Abuse: Integrating Research on Mechanisms, Treatment and Policies - Study 3","status":"RECRUITING","sponsor":"Wayne State University","isPivotal":false,"enrollment":24,"indication":"Opioid Abuse, Benzodiazepine Abuse","completionDate":"2026-12"},{"nctId":"NCT06826417","phase":"NA","title":"Pain, Anxiety and Anesthetic Satisfaction for Patient With Different State Anxiety Underwent Cataract Surgery With Topical Anesthesia","status":"RECRUITING","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":400,"indication":"Oral Anxiolytic, Phacoemulsification","completionDate":"2026-12-31"},{"nctId":"NCT00878514","phase":"Phase 1","title":"Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions; an Open, Randomised, Single Centre, Single Dose Study With Crossover Design in Healthy Subjects","status":"COMPLETED","sponsor":"Orion Corporation, Orion Pharma","isPivotal":false,"enrollment":18,"indication":"Healthy","completionDate":"2009-07"},{"nctId":"NCT04970342","phase":"Phase 1","title":"Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim: Evaluating Sensitivity to the Effects of Cannabis and Alprazolam","status":"COMPLETED","sponsor":"Timothy L. Brown","isPivotal":false,"enrollment":13,"indication":"Driving Behavior, Driving Under the Influence","completionDate":"2021-08-21"},{"nctId":"NCT03130842","phase":"Phase 2","title":"Comparing Efficacy of Oral Midazolam and Sublingual Alprazolam in Reducing Anxiety and Pain/Discomfort Related to Diagnostic Upper Gastrointestinal Endoscopy in Adults","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","isPivotal":true,"enrollment":136,"indication":"Diagnostic Esophagogastroduodenoscopy","completionDate":"2017-02-15"},{"nctId":"NCT01546896","phase":"Phase 4","title":"","status":"WITHDRAWN","sponsor":"Seoul National University Hospital","isPivotal":false,"enrollment":0,"indication":"Anxiety Disorder","completionDate":"2014-02"},{"nctId":"NCT04715269","phase":"Phase 1","title":"Effect of Alprazolam on Heart Rate and Acute Inflammatory Marker in Acute Coronary Syndrome Patients","status":"UNKNOWN","sponsor":"Sohaib Ashraf","isPivotal":false,"enrollment":48,"indication":"Acute Coronary Syndrome, Myocardial Infarction","completionDate":"2022-02-20"},{"nctId":"NCT01549691","phase":"Phase 4","title":"Assessment of Two Modes of Premedication in Surgery - PREMED Study","status":"COMPLETED","sponsor":"University Hospital, Angers","isPivotal":false,"enrollment":455,"indication":"Anxiety","completionDate":"2013-04"},{"nctId":"NCT04658732","phase":"Phase 1","title":"A Comparative Study of Oral Gabapentin, Oral Alprazolam and Intravenous Dexmedetomidine on Perioperative Anxiety and Pain During Posterior Segment Eye Surgery Under Peribulbar Block : a Randomized, Do","status":"UNKNOWN","sponsor":"Ehab Tarek Fahmy","isPivotal":false,"enrollment":45,"indication":"Sedation for Patients Undergoing Peribulbar Block","completionDate":"2021-08-01"},{"nctId":"NCT00635531","phase":"Phase 4","title":"A Randomized, Double-blind, Placebo-controlled Study of Xanax XR in the Treatment of Adolescents With a Primary Diagnosis of Panic Disorder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":16,"indication":"Panic Disorder","completionDate":"2004-09"},{"nctId":"NCT05737511","phase":"Phase 4","title":"Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial.","status":"NOT_YET_RECRUITING","sponsor":"Sultan Qaboos University","isPivotal":false,"enrollment":80,"indication":"Panic Disorder","completionDate":"2026-12-30"},{"nctId":"NCT03297944","phase":"Phase 4","title":"Alprazolam and Simulated Driving Performance: Next Day Effects","status":"COMPLETED","sponsor":"Marion Coe","isPivotal":false,"enrollment":15,"indication":"Psychomotor Impairment","completionDate":"2018-10-25"},{"nctId":"NCT05076617","phase":"Phase 3","title":"An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizu","status":"ENROLLING_BY_INVITATION","sponsor":"UCB Biopharma SRL","isPivotal":true,"enrollment":300,"indication":"Stereotypical Prolonged Seizures","completionDate":"2028-11-30"},{"nctId":"NCT01949038","phase":"Phase 2","title":"Comparison Between Sublingual and Oral Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy","status":"COMPLETED","sponsor":"Isfahan University of Medical Sciences","isPivotal":true,"enrollment":220,"indication":"Diagnostic Esophagogastroduodenoscopy","completionDate":"2013-01"},{"nctId":"NCT02033707","phase":"Phase 1","title":"Phase I Study Characterizing Effects of Hallucinogens and Other Drugs on Mood and Performance","status":"COMPLETED","sponsor":"Johns Hopkins University","isPivotal":false,"enrollment":20,"indication":"Healthy","completionDate":"2019-02"},{"nctId":"NCT01486615","phase":"Phase 4","title":"Premedication With Melatonin and Alprazolam Combination Versus Alprazolam or Melatonin Alone: a Randomized, Double Blind Placebo Controlled Study","status":"COMPLETED","sponsor":"B.P. Koirala Institute of Health Sciences","isPivotal":false,"enrollment":80,"indication":"Anxiety","completionDate":"2012-01"},{"nctId":"NCT03012334","phase":"Phase 1","title":"A Phase I, Randomized, Double-Blind, Placebo-Controlled, 5-Period, Cross-Over Study Assessing the Effects of Lasmiditan on Simulated Driving Performance in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Eli Lilly and Company","isPivotal":false,"enrollment":90,"indication":"Migraine","completionDate":"2017-06-08"},{"nctId":"NCT04857307","phase":"Phase 1","title":"A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of Staccato Alprazolam in Adolescent Study Participants With Epilepsy","status":"COMPLETED","sponsor":"UCB Biopharma SRL","isPivotal":false,"enrollment":14,"indication":"Epilepsy","completionDate":"2022-04-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Two to three times daily (IR) or once daily (XR)","formulation":"Tablet, Extended-release tablet, Orally disintegrating tablet, Oral solution"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"firstApprovalDate":"1981-10-16","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}